Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A pooled post-hoc analysis of the phase 3, randomized, placebo-controlled BLISS trials (1684 patients with active systemic lupus erythematosus (SLE)) was performed to evaluate the effect of belimumab on renal parameters in patients with renal involvement at baseline, and to explore whether belimumab offered additional renal benefit to patients receiving mycophenolate mofetil at baseline. In addition to belimumab or placebo, all patients received standard SLE therapy. Patients with severe active lupus nephritis were excluded from the trials. Over 52 weeks, rates of renal flare, renal remission, renal organ disease improvement (assessed by Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index and British Isles Lupus Assessment Group), proteinuria reduction, grade 3/4 proteinuria, and serologic activity favored belimumab, although the between-group differences in most renal outcomes were not significant. Among the 267 patients with renal involvement at baseline, those receiving mycophenolate mofetil or with serologic activity at baseline had greater renal organ disease improvement with belimumab than with placebo. Limitations of this analysis included the small patient numbers and the post-hoc nature of this pooled analysis. The results suggest that belimumab may offer renal benefit in patients with SLE. Further study is warranted in patients with severe active lupus nephritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Self-citationFurie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Mortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
Self-citationMycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., Eitner, F., Appel, G. B., Contreras, G., Lisk, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014460 · Cited by 642
Self-citationImmunologic Factors and Clinical Activity in Systemic Lupus Erythematosus
Schur, P. H., & Sandson, J. (1968) · New England Journal of Medicine · doi:10.1056/nejm196803072781004 · Cited by 587
Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572
Kelley’s Textbook of Rheumatology
Ehrlich, G. E. (2009) · JAMA · doi:10.1001/jama.2009.1254 · Cited by 568
Novel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationPetri, M., Stohl, W., Chatham, W., McCune, W. J., Chevrier, M., Ryel, J., Recta, V., Zhong, J., & Freimuth, W. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23678 · Cited by 428
Self-citationStohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., Clarke, A., Aranow, C., Wellborne, F. R., Abud‐Mendoza, C., Hough, D. R., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34400 · Cited by 418
Self-citationManzi, S., Sánchez-Guerrero, J., Merrill, J. T., Furie, R., Gladman, D., Navarra, S. V., Ginzler, E. M., D'Cruz, D. P., Doria, A., Cooper, S., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200831 · Cited by 411
Self-citationAlarcón‐Segovia, D., Tumlin, J. A., Furie, R. A., McKay, J. D., Cardiel, M. H., Strand, V., Bagin, R. G., Linnik, M. D., Hepburn, B., & LJP 394 Investigator Consortium (2003) · Arthritis & Rheumatism · doi:10.1002/art.10763 · Cited by 244
Ginzler, E. M., Wofsy, D., Isenberg, D., Gordon, C., Lisk, L., & Dooley, M. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25052 · Cited by 159
Self-citationTseng, C., Buyon, J. P., Kim, M., Belmont, M. H., Mackay, M. C., Diamond, B., Marder, G. S., Rosenthal, P., HAINES, K. A., Ilie, V., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22198 · Cited by 158
Sinclair, A., Appel, G. B., Dooley, M. A., Ginzler, E. M., Isenberg, D. A., Jayne, D. R. W., Wofsy, D., & Solomons, N. (2007) · Lupus · doi:10.1177/0961203307084712 · Cited by 121
Self-citationChanges in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995
Ward, M. M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.20.3136 · Cited by 92
Petri, M., Singh, S., TESFASYONE, H., & MALIK, A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090019 · Cited by 89
Clinical Features and Treatment of Systemic Lupus Erythematosus
Tassiulas, I. O., & Boumpas, D. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10075-0 · Cited by 37
Cited by
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Almaani, S., Meara, A., & Rovin, B. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05780616 · Cited by 930
Fanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Self-citationHoffman, W., Lakkis, F. G., & Chalasani, G. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09430915 · Cited by 482
Metadata
- Authors
- Dooley, M., Houssiau, F., Aranow, C., D’Cruz, D., Askanase, A., Roth, D., Zhong, Z., Cooper, S., Freimuth, W., & Ginzler, E.
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2012-12-21
- Volume
- 22
- Issue
- 1
- Pages
- 63-72
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2126846485
- Cited by
- 265
- References
- 19
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.